Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral -5

Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today - Yahoo Finance

AI-generated analysis

πŸ“Š Gilead Sciences closed at $140.45, rising 1.02% but underperforming the S&P 500's 1.18% gain and lagging behind the Nasdaq's 1.96% increase.

πŸ“‰ The stock had fallen 4.26% over the previous month while the broader Medical sector lost 1.56% and the S&P 500 gained 3.93%.

πŸ—“οΈ Earnings are anticipated on May 7, 2026, with consensus estimates predicting an EPS of $1.87 (a 3.31% year-over-year increase).

πŸ’° Revenue is forecast at $6.88 billion for the quarter, representing a 3.13% rise compared to the prior year's quarter.

πŸ“ˆ Annual Zacks Consensus Estimates project earnings of $8.65 per share and revenue of $30.15 billion, up +6.13% and +2.39% respectively from the former year.

πŸ”„ The 3-month consensus EPS estimate has moved 0.09% lower, reflecting recent analyst sentiment adjustments.

πŸ† Gilead currently holds a Zacks Rank of #3 (Hold), which sits below the top-tier ratings associated with strong stock outperformance.

πŸ’΅ Valuation metrics show a Forward P/E ratio of 16.07, indicating a discount compared to the industry average of 19.6.

πŸ“Š The company trades at a PEG ratio of 1.85, which is slightly higher than the medical sector's average of 1.6.

🏭 Gilead operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of #141 (bottom 43%).

πŸ” Research indicates that top 50% rated industries historically outperform bottom half industries by a factor of 2 to 1.

πŸ“ The article concludes with an invitation to download free reports on Gilead Sciences and the "7 Best Stocks for the Next 30 Days".

🌐 This content was originally published on Zacks Investment Research (zacks.com).

Bullish Signals
  • Gilead Sciences closed the day up +1.02% at $140.45, showing positive investor sentiment despite lagging slightly behind broader market gains.
  • The upcoming earnings report is expected on May 7, 2026, with consensus estimates predicting an EPS of $1.87 representing a 3.31% year-over-year increase.
  • Revenue expectations for the upcoming quarter stand at $6.88 billion, indicating projected growth of 3.13% from the prior-year quarter.
  • Full-year consensus estimates show earnings of $8.65 per share and revenue of $30.15 billion, representing positive growth changes of +6.13% and +2.39%, respectively.
  • Gilead Sciences trades at a Forward P/E ratio of 16.07, which signifies a discount compared to the industry average Forward P/E of 19.6.
  • The company's PEG ratio of 1.85 reflects its expected earnings growth trajectory within the Medical - Biomedical and Genetics sector.
  • Zacks Investment Research provides a proprietary Zacks Rank system with a proven, outside-audited track record of outperformance, offering investors valuable insights.
Risk Factors
  • Gilead Sciences stock underperformed the broader market today, rising only 1.02% compared to the S&P 500's gain of 1.18%.
  • Shares of the HIV and hepatitis C drugmaker have lost 4.26% over the past month while the Medical sector declined by 1.56%. The stock has failed to keep pace with the S&P 500's monthly gain of 3.93%.
  • The company holds a Zacks Rank of #3 (Hold), indicating neutral analyst sentiment that does not suggest outperformance compared to Strong Buy or Hold ratings.
  • Gilead Sciences has fallen into the bottom 43% of all industries based on its current Zacks Industry Rank of 141, which suggests a potential underperformance relative to industry peers.
  • Research indicates that top-rated industries outperform the bottom half by a factor of 2 to 1, placing Gilead's sector at a relative disadvantage in terms of average stock performance.
Full Analysis
Gilead Sciences (GILD) closed the trading day at $140.45, posting a gain of 1.02% but underperforming against broader market indices. The S&P 500 rose by 1.18%, the Nasdaq advanced 1.96%, and the Dow climbed 0.66%. While Gilead lagged its peer group, it remains one of the top movers in recent sessions with this daily move being the most recent gain, whereas over the past month, shares had declined 4.26%, a decline outpacing the medical sector's loss of 1.56% and contrasting sharply with the S&P 500's gain of 3.93% in the same period. Investors are closely watching the upcoming earnings release expected on May 7, 2026, where the company is anticipated to report an EPS of $1.87, representing a 3.31% increase over the prior year quarter. Revenue estimates for this quarter stand at $6.88 billion, up 3.13% from the previous-year quarter. For the full fiscal year, Zacks Consensus Estimates project earnings of $8.65 per share and revenue of $30.15 billion, indicating growth of 6.13% and 2.39%, respectively, compared to the prior year. In terms of valuation metrics, Gilead is trading with a Forward P/E ratio of 16.07, which represents a discount to the industry average Forward P/E of 19.6. The company's PEG ratio stands at 1.85 compared to an industry average of 1.6 for medical-biomedical and genetics stocks. Currently, Gilead holds a Zacks Rank of #3 (Hold), with the consensus EPS estimate having moved 0.09% lower over the past month. The broader industry where Gilead operates carries a Zacks Industry Rank of 141, placing it in the bottom 43% of all industries, though top-rated industries have historically outperformed the bottom half by a factor of 2 to 1.